Their DSMB meeting and deciding to expand the numb
Post# of 148183
(Total Views: 724)
Posted On: 11/18/2020 5:40:55 PM
Their DSMB meeting and deciding to expand the number of subjects from 300 to 500+ doesn't lend confidence, either. On the other hand 37% improvement in recoveries on lenzilumab versus placebo sounds decent.
Lenzilumab trial overview is here:
https://clinicaltrials.gov/ct2/show/NCT04351152
I didn't realize how many other anti-GM-CSF trials were going on for Covid, but there seem to be quite a few, all with different endpoints:
https://clinicaltrials.gov/ct2/results?cond=C...erm=GM-CSF
We are doing a non-lenzilumab anti-GM-CSF trial for Covid at my hospital system, which came through our IRB recently. It has a 43 day mortality primary endpoint.
Lots of different trials for Covid.
Hopefully leronlimab will enroll quickly and be one of the best.
Lenzilumab trial overview is here:
https://clinicaltrials.gov/ct2/show/NCT04351152
I didn't realize how many other anti-GM-CSF trials were going on for Covid, but there seem to be quite a few, all with different endpoints:
https://clinicaltrials.gov/ct2/results?cond=C...erm=GM-CSF
We are doing a non-lenzilumab anti-GM-CSF trial for Covid at my hospital system, which came through our IRB recently. It has a 43 day mortality primary endpoint.
Lots of different trials for Covid.
Hopefully leronlimab will enroll quickly and be one of the best.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼